ARS Pharma's needle-free allergy spray drives quarterly sales of $33.4m as costs fall

ARS Pharmaceuticals told investors on 5 November that its third-quarter 2026 revenue came to $37.7m, with its needle-free epinephrine nasal spray, neffy, accounting for $33.4m of that through US net sales. The remainder of the total was not itemised in the information available.

The company said neffy now commands 5% of the overall US market for severe allergic reaction treatment. The figure positions the spray as a small but measurable challenger in a category long dominated by injectable devices. The material available does not say how the share is calculated or how it compares with earlier quarters.

ARS also reported a sharp fall in selling, general and administrative spending. The size of the reduction and the period it is measured against were not provided. The company kept its target of reaching cash flow breakeven by the end of 2027.

On management, ARS named a new chief medical officer and a new chief legal officer. Names and start dates were not disclosed in the information reviewed.

In the pipeline, interim Phase 2b data for ARS-2 in flares of chronic spontaneous urticaria, a skin condition marked by recurring hives, are expected in the first quarter of 2027. No further details of the trial were supplied.